Post by Rohit Khuttan

When I wrote this blog, the argument was simple: life sciences commercial M&A is no longer just about buying capabilities. It is about buying the right to own more of the commercialization journey. Since the blog went live, two more deals have reinforced the point. Tredence acquired KMK Consulting to deepen its healthcare and life sciences analytics and consulting capabilities. Veeva acquired Copli and launched Veeva Falcon MLR, bringing agentic automation into one of the most painful bottlenecks in commercial content operations: MLR review. Different deals. Same signal. The life sciences commercial ecosystem is moving from point solutions to connected execution. Providers are not just trying to add more “nouns” to the portfolio — CRM, analytics, content, MLR, engagement, patient services. They are trying to own the “verbs”: decide, orchestrate, activate, review, comply, personalize, and prove impact. Read on: https://okt.to/xiV8sw Get in touch: Rohit Khuttan #LifeSciences #CommercialStrategy #PharmaTech